Atara Biotherapeutics Inc (ATRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.76+2.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ATRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 71.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -60.0% |
Growth built into the price is above our model estimate.
The price assumes 131.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ATRA — CFO transition
Dated 2026-06-26
Chief Accounting Officer — Yanina Grant-Huerta: The departure of the Chief Accounting Officer and appointment of an interim chief financial officer indicate significant changes in management.
Why it matters: The new director may affect important decisions. This can change the company's direction and performance.
Watch forThere are good changes in strategy or governance practices. These were reported in 6 months.
Also watch forThere are no clear improvements in governance or strategy. This is after 6 months.
Why it matters: The health care sector is maturing. If revenue growth re-accelerates, it could benefit Atara. This will show if the sector is improving.
Supportive ifThe health care sector reports revenue growth speeding up to 10% or more.
Worry ifSector revenue growth keeps slowing down below current levels.
Why it matters: A positive update on the FDA response can boost investor confidence and support future growth.
Supportive ifManagement says they made progress on the FDA Complete Response Letter for EBVALLO.
Worry ifNo progress reported on the FDA Complete Response Letter for EBVALLO in the next update.
Why it matters: The resubmission is important for Atara's future money from tab-cel. If it is successful, it could lead to approval and sales.
Supportive ifPierre Fabre submits the updated dataset for the tab-cel BLA by the end of Q3 2026.
Worry ifIf no resubmission happens by the end of Q3 2026, it shows delays with regulators.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$336 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $1,004 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,689 loss on $10,000 · 76.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash runway will show if Atara can pay for its operations. This affects how investors feel and future plans.
Watch forManagement says cash runway goes into mid-2027 during the Q3 2026 update.
Also watch forManagement says they have less cash than expected. This raises concerns about paying for operations.
Why it matters: Updates on cash and funding plans will show if Atara can sustain operations through 2026.
Worry ifManagement says cash and investments can fund operations until the end of 2026.
Less concerning ifManagement says cash and funding are not enough to support operations until the end of 2026.
Why it matters: Brian Cherry's appointment could signal changes in Atara's direction and focus. Investors will want to see how this affects company decisions.
Watch forManagement will share a new plan in the next earnings call.
Also watch forNo big changes in strategy are shared after the board appointment.
Why it matters: Changes in leadership can impact company plans and actions. Watching this can show Atara's future path.
Watch forGood changes in efficiency or strategy after the CFO change.
Also watch forBad news about operations or finances after the CFO change.
Why it matters: Keeping expenses low is crucial for Atara's cash runway and financial health.
Supportive ifOperating costs are below $6 million for the next quarter.
Worry ifOperating costs go over $6 million in the next quarter.
Why it matters: Reducing expenses is key to Atara's strategy for financial health. Investors need to see progress.
Supportive ifManagement says operating expenses will drop a lot in the next update.
Worry ifOperating expenses stay the same or go up in the next update.
Why it matters: The FDA's response could change when tabelecleucel gets approved.
Watch forThe FDA gives a positive response about the BLA resubmission.
Also watch forThe FDA raises new concerns or issues another Complete Response Letter.
Why it matters: Knowing the cash runway shows Atara can run operations without needing quick funds.
Supportive ifA report shows cash and equivalents are over $9 million as of September 30, 2026.
Worry ifCash and equivalents drop below $9 million by September 30, 2026.
Why it matters: A big drop in operating expenses shows management is good at cutting costs. This could help cash flow.
Supportive ifOperating expenses for Q2 2026 are down at least 60% compared to last year.
Worry ifOperating expenses do not drop much and stay the same or go up compared to last year.
Why it matters: The next earnings report will show Atara's financial health and progress. This is key for future growth.
Watch forThe earnings report shows revenue growth or better cost management from previous quarters.
Also watch forThe earnings report shows ongoing losses or falling revenue.
Why it matters: Better cash flow is key for funding operations through 2026. It shows financial stability.
Supportive ifCash flow from operations turns positive in Q2 2026.
Worry ifCash flow from operations remains negative in Q2 2026.
Why it matters: Having enough cash helps support ongoing work and projects.
Supportive ifAtara says it has enough cash and short-term investments to operate until mid-2027.
Worry ifAtara says it needs more cash or funding before mid-2027.
Why it matters: An update on the BLA could mean progress in getting tabelecleucel approved.
Supportive ifAtara sent the new data to the FDA for tabelecleucel.
Worry ifNo announcement regarding the BLA resubmission by the end of Q3 2026.